Starsource Multitrade Limited

Starsource Multitrade Limited

STARSOURCE.BO
Starsource Multitrade LimitedIN flagBombay Stock Exchange
84.08
INR
+4.00
- -
126.12MMarket Cap
Starsource Multitrade Limited
STARSOURCE.BO
(Bombay Stock Exchange)

Recent

price

84.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.51
Revenue per Share
0.02
5.65
0.95
1.61
1.87
-9.66
31.23
0.67
1.38
2.77
1.67
3.73
0.32
8
2.28
- -
-79.28
Basic EPS, GAAP
2.83
-9.88
-2.64
-1.1
-0.34
-13.94
42.73
-11.07
-36.56
32.22
-2.72
-2.19
-4.56
4.82
-1.88
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-10.16
-4.5
-3.55
-1.94
-0.13
-9.79
32.54
33.21
34.59
37.35
39.02
42.75
43.07
51.07
53.32
- -
10.02
Book Value per Share
24.12
29.77
30.73
32.34
34.14
24.49
66.82
67.49
68.86
71.63
73.3
77.03
77.35
85.35
87.58
- -
8.62
Tangible Book Value per Share
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
- -
1
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
5
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2,259.61
-2,261.15
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
8
1
2
3
-14
47
1
2
4
3
6
- -
12
3
-119
-119
Net Income, GAAP
- -
9.07
19.86
20.05
27.09
- -
12.21
86.82
18.98
15.98
19.51
- -
35.37
26.96
31.29
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2,255.27
-2,257.17
Profit Margin (%)
-6
13
14
14
18
21
85
84
84
87
109
62
61
61
106
13
13
Working Capital
5
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
36
45
46
49
51
37
100
101
103
107
110
116
116
128
131
13
13
Total Equity
-0.58
-2.69
-0.86
-2.32
-1.76
- -
-2.67
-0.42
-4.45
-3.66
-1.18
- -
-1.13
-1.14
-0.64
- -
- -
Return on Invested Capital (%)
-0.36
-138.91
-23.72
-58.6
-180.13
- -
274.52
2.04
4.06
7.7
4.37
- -
0.84
17
4.37
- -
-809.44
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
2.04
4.06
7.69
4.37
9.13
0.73
17
4.37
-249.5
-249.71
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
- -
2
Market Capitalization
172
172
166

Working Capital

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
7
- -
18
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
5
- -
5
Inventories
- -
- -
- -
Total Current Liabilities
6
- -
5
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.06%
-14.33%
-90.19%
Free Cash Flow
280.52%
680.81%
3,660.49%
Net Income, GAAP
-152.04%
-233.15%
-3,564.25%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
5
- -
- -
5

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.51
2.93
4.51
- -
8
2025
1.64
4.07
-1.17
-2.26
2.28
2026
-78.7
0.65
-0.58
-0.48
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Starsource Multitrade Limited engages in pharmaceutical trading and related services as part of the broader Chemo Pharma Laboratories Limited corporate group. It focuses on the sourcing, distribution, and commercialization of pharmaceutical products, chemicals, and related healthcare materials, supported by strategic partnerships and market channel development across its core markets. The company operates through diversified segments within the pharmaceutical ecosystem, emphasizing product sourcing, supply chain coordination, regulatory compliance, and customer relationship management to serve distributors, hospitals, clinics, and pharmaceutical manufacturers. Founding year and headquarters: established within India; headquarters are located in Mumbai, India, with activities and governance aligned to the Chemo Pharma Laboratories Limited corporate framework. The firm’s recent structural and strategic movements include ongoing alliance activity, adjustments to leadership and governance, and efforts to explore or pursue new business opportunities within the power and chemicals space alongside its pharmaceutical focus. As part of its latest developments, the company has reported board-level and management changes, reorganizations, and regulatory disclosures in connection with SEBI and stock exchange requirements, reflecting a broader strategic realignment and pursuit of growth avenues in its portfolio and markets. Industry and structure: operates in the Pharmaceuticals and General Trading sectors with potential ancillary activities in related chemical markets; maintains corporate relationships with Chemo Pharma Laboratories Limited as the parent or controlling entity, with possible subsidiary links and shared branding across its product and service lines. Geographic scope includes operations and market participation primarily within India, with distribution and trading activities that may extend to regional markets as part of its growth strategy. Key products and services: core product categories cover pharmaceutical products, active pharmaceutical ingredients (APIs) and related chemicals, specialty chemicals, medical supplies, and healthcare-focused trading services; services include product sourcing, import/export facilitation, regulatory compliance support, quality assurance coordination, logistics and distribution support, and channel management for resellers and end users. The company emphasizes a systematic listing of its offerings through product families and service types to provide clarity to customers and partners. It maintains a clear focus on expanding its product suite and market reach through strategic partnerships and potential acquisitions aligned with its stated growth plan.